



1633
#16
3-18-02
P.2

PATENT

RECEIVED

MAR 13 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

Applicant(s):

Ferrell *et al.*

Serial No.: 09/375,248

Filed: August 16, 1999

For: Screening and Therapy for
Lymphatic Disorders Involving the
Flt4 Receptor Tyrosine Kinase
(VEGFR-3)


Attorney Docket No.: 28967/35255A

Group Art Unit: 1633

Examiner: Eleanor Sorbello

) I hereby certify that this paper
) is being deposited with the
) United States Postal Service
) with sufficient postage as first
) class mail in an envelope
) addressed to: Commissioner
) for Patents, Washington, D.C.
) 20231 on this date:

) October 18, 2001
)
)
)

) 
) Nabeela R. McMillian
) Registration No. 43,363
) Agent for Applicants
)

**THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
Washington, D.C. 20231

Sir:

The patents and/or publications listed on the enclosed PTO Form-1449 are submitted pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the patents or publications are enclosed as necessary.

TIME OF FILING

This information disclosure statement is being filed:

- ☐ 1. with the application or within three months of the filing date of the application or date of entry into the national stage of an international application or, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last. In accordance with 37 CFR § 1.97(b), no certification or fee is required.

- ☐ 2. after the time period specified in paragraph 1 above, but, to the best of the undersigned's knowledge, before the mailing date of a final action under 37 CFR §1.113 or notice of allowance under 37 CFR §1.311. Therefore, in accordance with 37 CFR §1.97(c), submitted herewith is:

(check either A or B below)

- A. a certification as specified in 37 CFR §1.97(e).
B. the fee set forth in 37 CFR §1.17(p) for submission of an information disclosure statement under 37 CFR §1.97(c).
- ☒ 3. after the mailing date of either a final action under 37 CFR §1.113, but before payment of the issue fee. Therefore, Applicant submits herewith:
- A. a certification as specified in 37 CFR §1.97(e);

Applicants representative states that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

METHOD OF PAYMENT

- ☒ No fee is required.
- ☐ Attached is a check in the amount of \$_____.

The Commissioner is authorized to charge any fee deficiency required by this paper, or credit any overpayment, to Deposit Account No. 13-2855. A copy of this paper is enclosed.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300

By:


Nabeela R. McMillian
Reg. No: 43,363

October 18, 2001